Successful reduced-intensity stem cell transplantation (RIST) with mismatched cord blood in a 70-year-old patient with severe aplastic anemia (SAA)
Reduced-intensity stem cell transplantation (RIST) has been developed to reduce regimen-related toxicities (RRT) while preserving an adequate antitumor effect associated with allogeneic hematopoietic stem cell transplantation (allo-HSCT). RIST has been attempted in the treatment for various diseases. 1 However, feasibility of RIST for severe aplastic anemia (SAA) remains to be established, because it has a high risk for graft rejection. 2 With growing needs for alternative stem cell sources, use of cord blood (CB) as a stem cell resource can broaden the scope of patients who would benefit from allo-HSCT, but the data is limited. 3, 4 We will present a patient with SAA who had been successfully treated with RIST using CB.
A 70-year-old woman presented with petechiae and pancytopenia in June 2002. The complete blood count was white blood cell of 1.8 Â 10 9 /l, hemoglobin of 9.3 g/dl, and platelet of 18 Â 10 9 /l. Bone marrow biopsy disclosed fatty marrow with trilineage hypoplasia and normal karyotype, confirming a diagnosis of SAA. Her past medical history included rheumatoid arthritis (RA) with generalized joint deformities for 27 years, which had been treated with a variety of antirheumatic drugs including corticosteroids. Her RA had remained inactive with oral methylprednisolone 4 mg on every other day except for seasonal exacervation in winters.
Her SAA was not controlled by a combination therapy of cyclosporine and granulocyte colony-stimulating factor (G-CSF). She developed necrotizing gingivitis, which was refractory to antibiotic treatments. We therefore discontinued immunosuppressive therapy after 40 days. Allo-HSCT was considered, but no HLA-identical related donor was available. The patient was offered the option of RIST with CB after extensive discussion of the potential benefits, risks, and alternatives. Potential concerns discussed with the patient included safety of this treatment and possible graft failure. The PBSCT process proceeded with the patient's consent and was approved by the Institutional Review Board.
The patient received RIST using one antigen and threeallele-mismatched CB in September 2002. The preparative regimen consisted of fludarabine 25 mg/m 2 for 5 days, melphalan 80 mg/m 2 as a single dose, and fractionated total body irradiation (TBI) 4 Gy. Graft-versus-host disease (GVHD) prophylaxis was oral cyclosporine 3 mg/kg twice daily starting on day À1. Prefreezing CB contained 4.0 Â 10 7 /kg of all nucleated cells and 1.2 Â 10 5 /kg of CD34 þ cells. G-CSF 300 mg/m 2 was given from day 1 until neutrophil engraftment. On day 9, she developed 401C of fever and generalized erythema, which was felt to be grade 3 acute GVHD of the skin without liver or gut involvement. Skin biopsy confirmed GVHD, and clinical diagnosis of hyperacute GVHD was made. The erythema and fever disappeared immediately after the initiation of methylprednisolone 2 mg/kg. There was no episode of bacterial infection during neutropenia. Absolute neutrophil counts recovered to 0.5 Â 10 9 /l on day 12, and platelet count reached 20 Â 10 9 /l on day 52. Peripheral blood CD3-postitive lymphocytes were confirmed in complete (100%) donor chimerism on day 14 using the short tandem repeatpolymerase chain reaction method. 5 Cytomegalovirus antigenemia developed on day 39, which was successfully managed with pre-emptive treatment with gancyclovir and foscarnet. The only RRT observed within 100 days was mucositis (grade 2) and nausea (grade 3), according to the National Cancer Institute Common Toxicity Criteria (NCI-CTC) version 2.0. She is currently followed as an outpatient without any signs of chronic GVHD and remains 100% donor type chimerism on day 270. Her seasonal exacerbation of RA did not appear in the following winter on a maintenance dose of daily hydrocortisone of 20 mg.
The feasibility of applying CB to RIST has not been established. Donor T cells in the peripheral blood or bone marrow graft have been considered mature enough to create niche in the host hematopoiesis for the expansion of donor stem cells. However, this case suggests that RIST using CB may be feasible for the treatment of SAA. Given the naı¨ve phenotypes of T cells in CB, physicians believed that they are less alloreactive, 6 requiring intense myeloablation to achieve durable engraftment. On the other hand, the kinetics of lymphokine-activated killer cell induction and the responsiveness of CB to IL-2 stimulation have been reported to be identical to those of adult peripheral T cells. 7 CB progenitor cells produce larger hematopoietic colonies in vitro, better respond to growth factors, and expand in vitro for a longer duration than do adult cells. 8, 9 These unique properties of CB can theoretically offset the disadvantage of the small number of stem cells in CB.
CB transplantation is considered to be associated with decreased acute and chronic GVHD. 10 However, this patient developed hyperacute GVHD manifested by highgrade fever and generalized erythema before neutrophil engraftment. There are reports on acute GVHD before engraftment in the case of patients receiving CST, 11 suggesting the possibility of CB-associated GVT effects before engraftment.
11 CB T cells are possibly more immunocompetent than have been generally believed.
The optimal preparative regimen for CB-RIST is still unknown. Antithymocyte globulin (ATG) has been a key drug in myeloablative CB transplantation for engraftment. 12 In vivo T-cell depletion using ATG was considered necessary for durable engraftment. However, in CB-RIST, ATG possibly increases the rate of graft failure, 13 because recipient T cells remain relatively intact and CB T cells are attacked both by long-surviving ATG and by recipient T cells. In contrast, TBI may efficiently deplete recipient T cells without affecting donor cells, as suggested in a previous feasibility study using alternative donors.
14 Therefore, we omitted ATG and added TBI 4 Gy to fludarabine and melphalan, which successfully led to durable engraftment of CB. Furthermore, the immune system of the present patient may have been suppressed by aging and previous treatments for RA.
Once the feasibility of CB-RIST is confirmed, curative allo-HSCT will rapidly expand with the procedure. Considering the low toxicity of RIST using CB, most of those who are not amenable to allo-HSCT due to an advance age or comorbidity could be candidates for CB-RIST. We are now planning a phase I/II study to further investigate the feasibility and efficacy of RIST using CB. 
